Physician profile
Peter E Allotey
NPI 1164482808
$5,429.96
in general payments reported to CMS, 2019-2025
38 companies · $769 in 2025
The $769 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $895 · 2020: $588 · 2021: $765 · 2022: $521 · 2023: $1,020 · 2024: $872 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,661.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,063.00 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $606.27 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $506.10 | 2020-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $438.83 | 2019-2025 | |
| Glaxosmithkline, LLC. | $382.82 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $275.53 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.12 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $209.11 | 2019-2023 | |
| Amgen INC. | $148.36 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $138.10 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $134.07 | 2019-2023 | Spravato |
| Alnylam Pharmaceuticals INC. | $124.55 | 2023 | Onpattro |
| Phathom Pharmaceuticals, INC. | $124.47 | 2024 | Voquezna |
| Medtronic USA, INC. | $102.70 | 2020 | |
| Novartis Pharmaceuticals Corporation | $92.38 | 2019-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $88.68 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $82.65 | 2019-2020 | |
| Abbott Laboratories | $80.30 | 2021-2024 | Freestyle Libre, Freestyle Libre 3 |
| Exact Sciences Corporation | $66.49 | 2024-2025 | Cologuard Collection Kit |
| Abiomed | $54.14 | 2025 | |
| Lilly USA, LLC | $53.73 | 2021-2023 | Mounjaro |
| Esperion Therapeutics, INC. | $50.09 | 2021-2022 | |
| Dexcom, INC. | $47.67 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $42.22 | 2020-2021 | |
| Shield Therapeutics INC | $40.91 | 2023 | Accrufer |
| Atland Pharmaceuticals, LLC | $29.58 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Genzyme Corporation | $24.35 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.70 | 2021 | |
| Sanofi Pasteur INC. | $20.73 | 2023 | |
| Nestle Healthcare Nutrition INC. | $19.84 | 2021 | |
| Ardelyx, INC. | $17.15 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $16.70 | 2021 | |
| Boston Scientific Corporation | $16.20 | 2024 | Coveredge 32 |
| Takeda Pharmaceuticals U.S.A., INC. | $15.65 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.17 | 2019 | |
| Medline Industries LP | $14.43 | 2019 | |
| Hikma Pharmaceuticals USA | $14.31 | 2020 | |
| Medtronic, INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Allotey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.